Citi Maintains Buy Rating on AstraZeneca
Citi analyst Graham Parry has reaffirmed a buy rating for AstraZeneca, reflecting continued confidence in the company's outlook.
Stocks · News reference
Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push
Shah Capital sells 2.87M Novavax (NVAX) shares for $32.6M, ends activist campaign, and shifts to a family office structure.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
AstraZeneca Launches 'Meet Your Mark' Campaign to Promote Cancer Biomarker Testing
AstraZeneca has introduced a new public health campaign featuring actor Mark-Paul Gosselaar to encourage patients to discuss biomarker testing as a standard part of cancer care.
AstraZeneca Canada and Breast Cancer Canada Announce Research Funding
AstraZeneca Canada and Breast Cancer Canada are investing $200,000 in matched research funding to support initiatives addressing breast cancer survivorship.
AstraZeneca Enters Research Collaboration with Tremont AI
AstraZeneca has partnered with Tremont AI to develop and evaluate artificial intelligence models for preclinical safety assessment.
GSK Q3 2026 Earnings Call Transcript
GSK (NYSE:GSK) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For
GSK Reports Strong Third Quarter 2026 Financial Results
GSK reported third-quarter 2026 results, with core earnings per share of 54.6 pence, exceeding analyst consensus of 50.4 pence, driven by strong performance in its Specialty Medicines portfolio.